The brave new world of genetic testing in the management of the dyslipidaemias

Purpose of review With the exception of familial hypercholesterolaemia, the value of genetic testing for managing dyslipidaemias is not established. We review the genetics of major dyslipidaemias in context of clinical practice. Recent findings Genetic testing for familial hypercholesterolaemia is valuable to enhance diagnostic precision, cascade testing, risk prediction and the use of new medications. Hypertriglyceridaemia may be caused by rare recessive monogenic, or by polygenic, gene variants; genetic testing may be useful in the former, for which antisense therapy targeting apoC-III has been approved. Familial high-density lipoprotein deficiency is caused by specific genetic mutations, but there is no effective therapy. Familial combined hyperlipidaemia (FCHL) is caused by polygenic variants for which there is no specific gene testing panel. Familial dysbetalipoproteinaemia is less frequent and commonly caused by APOE ε2ε2 homozygosity; as with FCHL, it is responsive to lifestyle modifications and statins or/and fibrates. Elevated lipoprotein(a) is a quantitative genetic trait whose value in risk prediction over-rides genetic testing; treatment relies on RNA therapeutics. Summary Genetic testing is not at present commonly available for managing dyslipidaemias. Rapidly advancing technology may presage wider use, but its worth will require demonstration of cost-effectiveness and a healthcare workforce trained in genomic medicine.
Source: Current Opinion in Cardiology - Category: Cardiology Tags: MOLECULAR GENETICS: Edited by Ali J. Marian Source Type: research

Related Links:

How prevalent is statin use among terminally ill nursing home residents? Should statins be discontinued in those unlikely to benefit from continued use?Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
CONCLUSIONS: ACS patients with DM showed weaker coronary plaque regression than their counterparts. A significant correlation between the change in LDL-C level and ΔPAV in DM patients suggested that more intensive lipid-lowering therapy is required in ACS patients with DM. PMID: 32435011 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
There are clear gender differences in the medication prescribed in primary care to adults with or at high risk for heart disease, with women less apt than men to receive aspirin and statins, a new study indicates.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
Conditions:   Hypercholesterolemia;   Chronic Kidney Disease Requiring Chronic Dialysis Interventions:   Drug: Evolocumab + ezetimibe;   Drug: Placebo + ezetimibe Sponsors:   Policlinico Casilino ASL RMB;   IRCCS San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionAmong patients with CAD, BB exposure is associated with reduced risk of death. The association is strongest among those who have suffered MI. This favorable association appears durable beyond 3  years.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Hypercholesterolemia;   Chronic Kidney Disease Requiring Chronic Dialysis Interventions:   Drug: Evolocumab + ezetimibe;   Drug: Placebo + ezetimibe Sponsors:   Policlinico Casilino ASL RMB;   IRCCS San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Hepatitis D virus (HDV) infection may induce fulminant hepatitis in chronic hepatitis B patients (CHB) or rapid progression of CHB to cirrhosis or hepatocellular carcinoma. There is no effective treatment for ...
Source: Journal of Biomedical Science - Category: Biomedical Science Authors: Tags: Research Source Type: research
Pro-protein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are currently a class 1 recommendation for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients judged to be at very high risk for future ASCVD events in addition to maximally tolerated statins and ezetimibe.1 Recently, Inclisiran, a chemically synthesized small interfering RNA therapeutic agent that reduces hepatic synthesis of PCSK9 was developed with the intent to reduce plasma low-density lipoprotein-cholesterol (LDL-C) levels.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Nature Reviews Cardiology, Published online: 21 May 2020; doi:10.1038/s41569-020-0396-6Individuals with obesity have an increased prevalence of the Bacteroides 2 enterotype, which is associated with systemic inflammation and disease. However, statin therapy is associated with a reduced prevalence of this dysbiosis in individuals with obesity.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research
Statins are associated with muscle-related adverse events, but few studies have investigated the association with fall-related hospitalizations among residents of long-term care facilities (LTCFs).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research
More News: Cardiology | Cholesterol | Genetics | Heart | Statin Therapy